Bridge Therapeutics

AL - BirminghamBiotechnology1 H-1B visas (FY2023)

Focus: Bridge Therapeutics is a public-stage specialty pharmaceutical company headquartered in Birmingham, AL, focused on pain treatments and a diversified portfolio across cardiovascular, neurology, immunology, gastroenterology, and infectious disease indications.

Cardiovascular Neurology Immunology Gastroenterology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Bridge Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Bridge Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

ZUBSOLV

Opioid use disorder

$28M Part D

Peak6.3yr

Revenue anchor representing 73% of total company revenue with 8+ years of exclusivity remaining; primary cash generator funding operations.

Help build intelligence for Bridge Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

ZUBSOLV generates $28M in Part D spending and maintains peak lifecycle status through 2032, providing a stable revenue base
Portfolio includes emerging assets like RECORLEV (levoketoconazole) for Cushing's syndrome with $10M Part D spending and LOE protection until 2040
Public company status offers equity upside potential and access to capital markets for R&D expansion

Watch Out For

Zero active clinical trials (Phase 1-3) and an empty pipeline signal minimal internal R&D momentum and limited near-term catalysts
Extreme revenue concentration—73% dependent on a single product (ZUBSOLV)—creates vulnerability to competitive pressure or market disruption
Current hiring freeze (zero active job postings) indicates organizational contraction or restructuring, limiting career mobility

Generated by Claude from Bridge Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

RECORLEV

Cushing's syndrome

$10M Part D

Peak13.8yr

Second-largest revenue contributor with longest patent protection (15+ years); CYP11B1 inhibitor with meaningful market validation.

HEMADY

Multiple myeloma, diabetic macular edema, lymphoma

$159K Part D

Peak11.6yr

Small-revenue niche indicated product with LOE protection through 2037; specialty oncology and ophthalmology positioning.

CARBIDOPA

Parkinson's disease

Post-LOE

Generic asset with eroded competitive position; represents legacy revenue with limited margin contribution.

LOPERAMIDE HYDROCHLORIDE

Diarrhea

Post-LOE

Post-LOE generic antidiarrheal; minimal revenue significance and shrinking market presence.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 33 approved products

Top TAs: Neurology, Gastroenterology, Immunology

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Peak7 (21%)

LOE Approaching2 (6%)

Post-LOE24 (73%)

33 total products

Therapeutic Area Focus

9 marketed

5 marketed

5 marketed

5 marketed

5 marketed

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

bisoprolol fumarate and hydrochlorothiazide

CLINICAL PHARMACOLOGY Bisoprolol fumarate and HCTZ have been used individually and in combination for the treatment of hypertension. The antihypertensive effects of these agents are additive; HCTZ 6.25 mg significantly increases the antihypertensive effect of bisoprolol fumarate. The incidence of hypokalemia with the bisoprolol fumarate and HCTZ 6.25 mg combination (B/H) is significantly lower than with HCTZ 25 mg. In clinical trials of bisoprolol fumarate and hydrochlorothiazide tablets, mean changes in serum potassium for patients treated with bisoprolol fumarate and hydrochlorothiazide tablets 2.5/6.25 mg, 5/6.25 mg or 10/6.25 mg or placebo were less than ± 0.1 mEq/L. Mean changes in serum potassium for patients treated with any dose of bisoprolol in combination with HCTZ 25 mg ranged from -0.1 to -0.3 mEq/L. Bisoprolol fumarate is a beta 1 -selective (cardioselective) adrenoceptor blocking agent without significant membrane stabilizing or intrinsic sympathomimetic activities in its therapeutic dose range. At higher doses (≥ 20 mg) bisoprolol fumarate also inhibits beta 2 -adrenoreceptors located in bronchial and vascular musculature. To retain relative selectivity, it is important to use the lowest effective dose. Hydrochlorothiazide is a benzothiadiazine diuretic. Thiazides affect renal tubular mechanisms of electrolyte reabsorption and increase excretion of sodium and chloride in approximately equivalent amounts. Natriuresis causes a secondary loss of potassium. Pharmacokinetics and Metabolism Bisoprolol fumarate and hydrochlorothiazide tablets In healthy volunteers, both bisoprolol fumarate and hydrochlorothiazide are well absorbed following oral administration of bisoprolol fumarate and hydrochlorothiazide tablets. No change is observed in the bioavailability of either agent when given together in a single tablet. Absorption is not affected whether bisoprolol fumarate and hydrochlorothiazide tablets is taken with or without food. Mean peak bisoprolol fumarate plasma concentrations of about 9.0 ng/mL, 19 ng/mL and 36 ng/mL occur approximately 3 hours after the administration of the 2.5 mg/6.25 mg, 5 mg/6.25 mg and 10 mg/6.25 mg combination tablets, respectively. Mean peak plasma hydrochlorothiazide concentrations of 30 ng/mL occur approximately 2.5 hours following the administration of the combination. Dose proportional increases in plasma bisoprolol concentrations are observed between the 2.5 and 5, as well as between the 5 and 10 mg doses. The elimination T1/2 of bisoprolol ranges from 7 to 15 hours, and that of hydrochlorothiazide ranges from 4 to 10 hours. The percent of dose excreted unchanged in urine is about 55% for bisoprolol and about 60% for hydrochlorothiazide. Bisoprolol Fumarate The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%. The first pass metabolism of bisoprolol fumarate is about 20%. The pharmacokinetic profile of bisoprolol fumarate has been examined following single doses and at

Rare Diseases

2 marketed

Respiratory

2 marketed

Bridge Therapeutics

About Bridge Therapeutics

Why Work Here

Key Products

Watch Out For

Products & Portfolio (22)

Key Products by Revenue

Other Products (20)

Open Jobs (0)

Visa Sponsorship